GlassScriptPhysician profile
Hemant Pandey
NPI 1275535403
$229,684.30
in general payments reported to CMS, 2019-2025
84 companies · $139K in 2025
The $139K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $8,590 · 2020: $3,701 · 2021: $14K · 2022: $6,906 · 2023: $7,993 · 2024: $49K · 2025: $139K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $64K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $58K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Travel and Lodging: $20K · Food and Beverage: $11K · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $63,976.25 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $58,410.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,900.00 |
| Travel and Lodging | $20,034.29 |
| Food and Beverage | $11,482.49 |
| Education | $275.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $93,500.94 | 2019-2025 | |
| Lilly USA, LLC | $30,452.51 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Novo Nordisk As | $28,028.69 | 2025 | |
| C2n Diagnostics, LLC | $18,374.41 | 2025 | Precivityad2 |
| Eli Lilly and Company | $13,698.09 | 2022-2025 | Kisunla |
| Biohaven Pharmaceuticals, INC. | $12,393.78 | 2020-2021 | |
| Boston Scientific Corporation | $11,079.86 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $5,679.34 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $5,250.00 | 2023 | Rexulti |
| Abbvie INC. | $2,329.17 | 2019-2025 | |
| Ucb, INC. | $1,138.05 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Jazz Pharmaceuticals INC. | $422.81 | 2019-2025 | |
| Biogen, INC. | $388.12 | 2019-2025 | Tysabri, Vumerity, Spinraza |
| Mdd US Operations, LLC | $381.71 | 2019-2025 | Apokyn, Apokyn |
| Inspire Medical Systems, INC. | $378.37 | 2024-2025 | Inspire |
Show all 78 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $367.10 | 2019-2025 | Ingrezza, Ongentys |
| Argenx US, INC. | $346.03 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $291.31 | 2019-2025 | Uplizna |
| Celgene Corporation | $263.71 | 2023-2025 | Zeposia |
| Lundbeck LLC | $256.27 | 2019-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $254.61 | 2019-2024 | Ultomiris |
| Genzyme Corporation | $250.61 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $242.27 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $240.08 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $232.17 | 2019-2025 | Rytary, Crexont |
| Mallinckrodt Hospital Products INC. | $219.69 | 2020-2025 | Acthar |
| Pfizer INC. | $202.40 | 2023-2025 | |
| Allergan, INC. | $186.95 | 2019-2021 | |
| Novo Nordisk INC | $170.53 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $170.46 | 2024-2025 | Wainua |
| Emd Serono, INC. | $163.55 | 2019-2020 | |
| Grifols USA, LLC | $144.58 | 2019-2024 | Gamunex-C |
| Otsuka America Pharmaceutical, INC. | $144.44 | 2023-2024 | Rexulti |
| Acadia Pharmaceuticals INC | $134.19 | 2019-2025 | Nuplazid |
| Sk Life Science, INC. | $129.05 | 2021-2025 | |
| Csl Behring | $120.60 | 2019-2023 | Hizentra, Privigen |
| Teva Pharmaceuticals USA, INC. | $118.92 | 2022-2023 | Austedo Xr, Austedo |
| Harmony Biosciences LLC | $114.22 | 2023-2025 | Wakix |
| Neurelis, INC. | $112.57 | 2022-2025 | Valtoco |
| Takeda Pharmaceuticals U.S.A., INC. | $84.60 | 2023-2024 | Hyqvia, Gammagard |
| Genentech USA, INC. | $77.24 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Alnylam Pharmaceuticals INC. | $73.34 | 2022-2024 | Amvuttra, Givlaari |
| Horizon Therapeutics Plc | $65.18 | 2022-2023 | Uplizna |
| Akcea Therapeutics, INC. | $62.01 | 2019-2020 | |
| Tg Therapeutics, INC. | $59.99 | 2023-2025 | |
| Impel Pharmaceuticals INC. | $56.71 | 2022-2023 | Trudhesa |
| Ge Healthcare | $55.15 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $48.52 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $47.84 | 2019 | |
| Abbott Laboratories | $46.26 | 2024-2025 | Eterna, Amplatzer Talisman |
| Acorda Therapeutics, INC | $43.16 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $42.45 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $35.79 | 2023 | Aptiom |
| Medtronic USA, INC. | $34.90 | 2019 | |
| Octapharma USA, INC. | $29.61 | 2024 | Panzyga |
| Avid Radiopharmaceuticals, INC. | $27.59 | 2025 | |
| Livanova USA, INC. | $26.53 | 2019 | |
| Assertio Therapeutics, INC. | $26.08 | 2019-2020 | |
| Avion Pharmaceuticals | $24.37 | 2023 | Dhivy |
| Otto Bock Healthcare LP | $24.07 | 2023 | |
| Shire North American Group INC | $23.03 | 2019 | |
| Aquestive Therapeutics, INC. | $21.76 | 2020 | |
| Averitas Pharma INC. | $21.62 | 2024 | Qutenza |
| Noctrix Health, INC. | $21.51 | 2025 | Nidra |
| Janssen Biotech, INC. | $21.30 | 2025 | |
| Corium, LLC | $20.79 | 2022 | |
| Kyowa Kirin, INC. | $19.45 | 2023 | Nourianz |
| Tanabe Pharma America, INC. | $17.91 | 2024 | |
| Banner Life Sciences, LLC | $17.09 | 2023 | |
| Nevro Corp. | $17.03 | 2019 | |
| Scilex Pharmaceuticals INC. | $16.87 | 2024 | |
| Catalyst Pharmaceuticals, INC. | $16.42 | 2019 | |
| Vertiflex, INC. | $16.33 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.66 | 2019 | |
| Greenwich Biosciences, INC. | $14.47 | 2020 | |
| Linus Health, INC. | $14.12 | 2024 | Core Cognitive Evaluation |
| Merck Sharp & Dohme LLC | $13.81 | 2019 | |
| Alfasigma USA, INC. | $12.58 | 2022 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$47,551.92 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hemant Pandey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.